hTACI(TNFRSF13B) Mouse
Product Name
hTACI(TNFRSF13B) Mouse
Product ID
C001725
Strain Name
C57BL/6NCya-Tnfrsf13btm1(hTNFRSF13B)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “hTACI(TNFRSF13B) Mouse (Catalog C001725) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
TNFRSF13B
Gene Alias
CVID, RYZN, TACI, CD267, CVID2, IGAD2, TNFRSF14B
NCBI ID
Chromosome
Chr 17 (Human)
MGI ID
Datasheet
Strain Description
The TNFRSF13B gene encodes the transmembrane activator and CAML interactor (TACI), a receptor belonging to the tumor necrosis factor receptor superfamily, predominantly expressed on B lymphocytes. TACI plays a critical role in humoral immunity by recognizing the TNF ligands B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) [1]. Upon ligand binding, TACI modulates intracellular signaling pathways, including NFAT, AP1, and NF-κB, which are essential for B cell survival, maturation into plasma cells, and the production of immunoglobulins [2]. Notably, TNFRSF13B is highly polymorphic, and specific genetic variants are strongly associated with the pathogenesis of common variable immunodeficiency (CVID), a primary immunodeficiency characterized by hypogammaglobulinemia and increased susceptibility to infection [3]. While the precise mechanisms by which these variants contribute to disease are still under investigation, they often result in impaired TACI function, disrupting normal B cell development and antibody responses [4]. Further research into the regulation and function of TACI is crucial for understanding the complex etiology of CVID and for developing targeted therapeutic strategies for this and potentially other immune-related disorders.
The hTACI(TNFRSF13B) mouse is a humanized model constructed by replacing the exon 2 plus partial intron 2 of the mouse Tnfrsf13b gene in situ with the Kozak-TNFRSF13B chimeric CDS-3'UTR of mouse Tnfrsf13b-WPRE-BGH pA cassette. The hTACI(TNFRSF13B) mice can be used for studies on common variable immunodeficiency (CVID), and pathogenesis of immune-related diseases, as well as for TNFRSF13B-targeted drug development.
Reference
Salzer U, Grimbacher B. TACI deficiency - a complex system out of balance. Curr Opin Immunol. 2021 Aug;71:81-88.
de Mattos Barbosa MG, Lefferts AR, Huynh D, Liu H, Zhang Y, Fu B, Barnes J, Samaniego M, Bram RJ, Geha RS, Shikanov A, Prak ETL, Farkash EA, Platt JL, Cascalho M. TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI Insight. 2021 Sep 8;6(17):e150483.
Yeo SC, Barratt J. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii9-ii18.
Zhang J, van Oostrom D, Li J, Savelkoul HFJ. Innate Mechanisms in Selective IgA Deficiency. Front Immunol. 2021 Apr 26;12:649112.
Strain Strategy
The coding sequences of exon 2 plus partial intron 2 of mouse Tnfrsf13b were replaced with the "Kozak-TNFRSF13B chimeric CDS-3'UTR of mouse Tnfrsf13b-WPRE-BGH pA" cassette.
Figure 1. Gene editing strategy of hTACI(TNFRSF13B) Mice.
Application Area
TNFRSF13B-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of common variable immunodeficiency (CVID).
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
